頑固性心力衰竭ppt課件-資料下載頁
2025-05-12 13:42本頁面
【正文】 75％，有心臟移植指征在等待手術(shù)期間，應用體外機械輔助泵可維持心臟功能，能延長患者壽命； ? 心室減容術(shù) 和 動力性心肌成形術(shù) 的效果尚待明確 外科治療 ? 心室減容術(shù) 和 動力性心肌成形術(shù) 的效果尚待明確 Stage D Therapy Referral for cardiac transplantation in potentially eligible patients is remended for patients with refractory endstage HF. The effectiveness of mitral valve repair or replacement is not established for severe secondary mitral regurgitation in refractory endstage HF. Surgical Therapy II IIaIIa IIbIIb IIIIIII IIa IIb III Dr Michel Mirowski, inventor of ICD. ? 心臟復律和人工心臟起搏 The CorCap is designed to: ? Provide enddiastolic ventricular support to reduce wall stress and myocardial stretch ? Negate the stimuli for ventricular remodeling and promote myocardial reverse remodeling ? Reverse progressive dilation and improve cardiac function and patient functional status CorCap? Cardiac Support Device CorCap? Cardiac Support Device ?Proofofconcept studies pleted in 3 different animal models of heart failure ?Human safety experience demonstrates structural amp。 clinical benefit out to 4 years I IIa IIb III Stage D Therapy Consideration of an LV assist device as permanentor “destination” therapy is reasonable in highly selected patients with refractory endstage HF and an estimated 1year mortality over 50% with medical therapy. Pulmonary artery catheter placement may be reasonable to guide therapy in patients with refractory endstage HF and persistently severe symptoms. Device Use II IIaIIa IIbIIb IIIIIIStage D Therapy Referral of patients with refractory endstage HF to an HF program with expertise in the management of refractory HF is useful. Referral to an HF Program II IIaIIa IIb IIIIIIStage D Therapy Options for endoflife care should be discussed with the patient and family when severe symptoms in patients with refractory endstage HF persist despite application of all remended therapies. Discussion of Options for EndofLife Care II IIaIIa IIb IIIIIIStage D Therapy: Partial left ventriculectomy is not remended inpatients with nonischemic cardiomyopathy and refractory endstage HF. Routine intermittent infusions of positive inotropic agents are not remended for patients with refractory endstage HF. II IIaIIa IIb IIIIIIII IIaIIa IIb IIIIIINOT Remended
教學課件相關(guān)推薦
鄂ICP備17016276號-1